Expand ATHE Menu
ATHE MENU

ATHE Latest Press Releases

-- April 27, 2026 --

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy Globe Newswire 7:25 AM

-- April 22, 2026 --

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology Globe Newswire 7:25 AM

-- April 17, 2026 --

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors Globe Newswire 7:25 AM

-- April 16, 2026 --

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting Globe Newswire 7:25 AM

-- April 15, 2026 --

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy Globe Newswire 7:25 AM

-- March 30, 2026 --

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program Globe Newswire 7:25 AM

-- March 9, 2026 --

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit Globe Newswire 7:25 AM

-- March 4, 2026 --

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor Globe Newswire 7:25 AM

-- March 2, 2026 --

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments Globe Newswire 7:25 AM

-- January 30, 2026 --

Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update Globe Newswire 7:25 AM

-- January 21, 2026 --

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 Globe Newswire 7:25 AM
Market Data Delayed 15 Minutes